Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if carfilzomib and vorinostat combined
with gemcitabine, busulfan, and melphalan with a stem cell transplant will help to control
multiple myeloma (MM). Researchers also want to learn about the safety and effectiveness of
this combination.